Skip to main content
Top
Published in: BMC Nephrology 1/2013

Open Access 01-12-2013 | Research article

Diastolic dysfunction is associated with an increased risk of contrast-induced nephropathy: a retrospective cohort study

Authors: Hyang Mo Koo, Fa Mee Doh, Kwang Il Ko, Chan Ho Kim, Mi Jung Lee, Hyung Jung Oh, Seung Hyeok Han, Beom Seok Kim, Tae-Hyun Yoo, Shin-Wook Kang, Kyu Hun Choi

Published in: BMC Nephrology | Issue 1/2013

Login to get access

Abstract

Background

Contrast-induced nephropathy (CIN) is the third leading cause of hospital-acquired acute kidney injury, and it is associated with poor long-term clinical outcomes. Although systolic heart failure is a well-known risk factor for CIN, no studies have yet evaluated the association between diastolic dysfunction and CIN.

Methods

We conducted a retrospective study of 735 patients who underwent percutaneous transluminal coronary angioplasty (PTCA) and had an echocardiography performed within one month of the procedure at our institute, between January 2009 and December 2010. CIN was defined as an increase of ≥ 0.5 mg/dL or ≥ 25% in serum creatinine level during the 72 hours following PTCA.

Results

CIN occurred in 64 patients (8.7%). Patients with CIN were older, had more comorbidities, and had an intra-aortic balloon pump (IABP) placed more frequently during PTCA than patients without CIN. They showed greater high-sensitivity C-reactive protein (hs-CRP) levels and lower estimated glomerular filtration rates (eGFR). Echocardiographic findings revealed lower ejection fraction and higher left atrial volume index and E/E’ in the CIN group compared with non-CIN group. When patients were classified into 3 groups according to the E/E’ values of 8 and 15, CIN occurred in 42 (21.6%) patients in the highest tertile compared with 20 (4.0%) in the middle and 2 (4.3%) in the lowest tertile (p < 0.001). In multivariate logistic regression analysis, E/E’ > 15 was identified as an independent risk factor for the development of CIN after adjustment for age, diabetes, dose of contrast media, IABP use, eGFR, hs-CRP, and echocardiographic parameters [odds ratio (OR) 2.579, 95% confidence interval (CI) 1.082-5.964, p = 0.035]. In addition, the area under the receiver operating characteristic curve of E/E’ was 0.751 (95% CI 0.684-0.819, p < 0.001), which was comparable to that of ejection fraction and left atrial volume index (0.739 and 0.656, respectively, p < 0.001).

Conclusions

This study demonstrated that, among echocardiographic variables, E/E' was an independent predictor of CIN. This in turn suggests that diastolic dysfunction may be a useful parameter in CIN risk stratification.
Appendix
Available only for authorised users
Literature
1.
go back to reference Goldfarb S, McCullough PA, McDermott J, Gay SB: Contrast-induced acute kidney injury: specialty-specific protocols for interventional radiology, diagnostic computed tomography radiology, and interventional cardiology. Mayo Clin Proc Mayo Clin. 2009, 84: 170-179.CrossRefPubMed Goldfarb S, McCullough PA, McDermott J, Gay SB: Contrast-induced acute kidney injury: specialty-specific protocols for interventional radiology, diagnostic computed tomography radiology, and interventional cardiology. Mayo Clin Proc Mayo Clin. 2009, 84: 170-179.CrossRefPubMed
2.
go back to reference Finn WF: The clinical and renal consequences of contrast-induced nephropathy. Nephrol, Dial, Transplantat. 2006, 21: i2-10.CrossRef Finn WF: The clinical and renal consequences of contrast-induced nephropathy. Nephrol, Dial, Transplantat. 2006, 21: i2-10.CrossRef
3.
4.
go back to reference Bartholomew BA, Harjai KJ, Dukkipati S, Boura JA, Yerkey MW, Glazier S, Grines CL, O'Neill WW: Impact of nephropathy after percutaneous coronary intervention and a method for risk stratification. Am J Cardiol. 2004, 93: 1515-1519.CrossRefPubMed Bartholomew BA, Harjai KJ, Dukkipati S, Boura JA, Yerkey MW, Glazier S, Grines CL, O'Neill WW: Impact of nephropathy after percutaneous coronary intervention and a method for risk stratification. Am J Cardiol. 2004, 93: 1515-1519.CrossRefPubMed
5.
go back to reference Goldenberg I, Matetzky S: CMAJ: Can Med Assoc J = Journal de l'Association Medicale Canadienne. 2005, 172: 1461-1471.CrossRef Goldenberg I, Matetzky S: CMAJ: Can Med Assoc J = Journal de l'Association Medicale Canadienne. 2005, 172: 1461-1471.CrossRef
6.
go back to reference Mehran R, Nikolsky E: Contrast-induced nephropathy: definition, epidemiology, and patients at risk. Kidney Int Suppl. 2006, 100: 11-15.CrossRef Mehran R, Nikolsky E: Contrast-induced nephropathy: definition, epidemiology, and patients at risk. Kidney Int Suppl. 2006, 100: 11-15.CrossRef
7.
go back to reference Rosenstock JL, Gilles E, Geller AB, Panagopoulos G, Mathew S, Malieckal D, DeVita MV, Michelis MF: Impact of heart failure on the incidence of contrast-induced nephropathy in patients with chronic kidney disease. Int Urol Nephrol. 2010, 42: 1049-1054.CrossRefPubMed Rosenstock JL, Gilles E, Geller AB, Panagopoulos G, Mathew S, Malieckal D, DeVita MV, Michelis MF: Impact of heart failure on the incidence of contrast-induced nephropathy in patients with chronic kidney disease. Int Urol Nephrol. 2010, 42: 1049-1054.CrossRefPubMed
8.
go back to reference Nikolsky E, Mehran R, Turcot D, Aymong ED, Mintz GS, Lasic Z, Lansky AJ, Tsounias E, Moses JW, Stone GW, et al: Impact of chronic kidney disease on prognosis of patients with diabetes mellitus treated with percutaneous coronary intervention. Am J Cardiol. 2004, 94: 300-305.CrossRefPubMed Nikolsky E, Mehran R, Turcot D, Aymong ED, Mintz GS, Lasic Z, Lansky AJ, Tsounias E, Moses JW, Stone GW, et al: Impact of chronic kidney disease on prognosis of patients with diabetes mellitus treated with percutaneous coronary intervention. Am J Cardiol. 2004, 94: 300-305.CrossRefPubMed
9.
go back to reference Pannu N, Wiebe N, Tonelli M: Prophylaxis strategies for contrast-induced nephropathy. JAMA. 2006, 295: 2765-2779.CrossRefPubMed Pannu N, Wiebe N, Tonelli M: Prophylaxis strategies for contrast-induced nephropathy. JAMA. 2006, 295: 2765-2779.CrossRefPubMed
10.
go back to reference Barrett BJ, Parfrey PS: Clinical practice. Preventing nephropathy induced by contrast medium. New Engl J Med. 2006, 354: 379-386.CrossRefPubMed Barrett BJ, Parfrey PS: Clinical practice. Preventing nephropathy induced by contrast medium. New Engl J Med. 2006, 354: 379-386.CrossRefPubMed
11.
go back to reference Nagueh SF, Appleton CP, Gillebert TC, Marino PN, Oh JK, Smiseth OA, Waggoner AD, Flachskampf FA, Pellikka PA, Evangelisa A: Recommendations for the evaluation of left ventricular diastolic function by echocardiography. Eur J Echocardiogr. 2009, 10: 165-193.CrossRefPubMed Nagueh SF, Appleton CP, Gillebert TC, Marino PN, Oh JK, Smiseth OA, Waggoner AD, Flachskampf FA, Pellikka PA, Evangelisa A: Recommendations for the evaluation of left ventricular diastolic function by echocardiography. Eur J Echocardiogr. 2009, 10: 165-193.CrossRefPubMed
12.
go back to reference Ommen SR, Nishimura RA, Appleton CP, Miller FA, Oh JK, Redfield MM, Tajik AJ: Clinical utility of Doppler echocardiography and tissue Doppler imaging in the estimation of left ventricular filling pressures: A comparative simultaneous Doppler-catheterization study. Circulation. 2000, 102: 1788-1794.CrossRefPubMed Ommen SR, Nishimura RA, Appleton CP, Miller FA, Oh JK, Redfield MM, Tajik AJ: Clinical utility of Doppler echocardiography and tissue Doppler imaging in the estimation of left ventricular filling pressures: A comparative simultaneous Doppler-catheterization study. Circulation. 2000, 102: 1788-1794.CrossRefPubMed
13.
go back to reference Sohn DW, Song JM, Zo JH, Chai IH, Kim HS, Chun HG, Kim HC: Mitral annulus velocity in the evaluation of left ventricular diastolic function in atrial fibrillation. J Am Soc Echocardiogr. 1999, 12: 927-931.CrossRefPubMed Sohn DW, Song JM, Zo JH, Chai IH, Kim HS, Chun HG, Kim HC: Mitral annulus velocity in the evaluation of left ventricular diastolic function in atrial fibrillation. J Am Soc Echocardiogr. 1999, 12: 927-931.CrossRefPubMed
14.
go back to reference Mehran R, Aymong ED, Nikolsky E, Lasic Z, Iakovou I, Fahy M, Mintz GS, Lansky AJ, Moses JW, Stone GW, et al: A simple risk score for prediction of contrast-induced nephropathy after percutaneous coronary intervention: development and initial validation. J Am Coll Cardiol. 2004, 44: 1393-1399.PubMed Mehran R, Aymong ED, Nikolsky E, Lasic Z, Iakovou I, Fahy M, Mintz GS, Lansky AJ, Moses JW, Stone GW, et al: A simple risk score for prediction of contrast-induced nephropathy after percutaneous coronary intervention: development and initial validation. J Am Coll Cardiol. 2004, 44: 1393-1399.PubMed
15.
go back to reference Mehta RL, Kellum JA, Shah SV, Molitoris BA, Ronco C, Warnock DG, Levin A: Acute Kidney Injury Network: report of an initiative to improve outcomes in acute kidney injury. Crit Care. 2007, 11: R31-CrossRefPubMedPubMedCentral Mehta RL, Kellum JA, Shah SV, Molitoris BA, Ronco C, Warnock DG, Levin A: Acute Kidney Injury Network: report of an initiative to improve outcomes in acute kidney injury. Crit Care. 2007, 11: R31-CrossRefPubMedPubMedCentral
16.
go back to reference Levey AS, Bosch JP, Lewis JB, Greene T, Rogers N, Roth D: A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group. Ann Intern Med. 1999, 130: 461-470.CrossRefPubMed Levey AS, Bosch JP, Lewis JB, Greene T, Rogers N, Roth D: A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group. Ann Intern Med. 1999, 130: 461-470.CrossRefPubMed
17.
go back to reference Devereux RB, Alonso DR, Lutas EM, Gottlieb GJ, Campo E, Sachs I, Reichek N: Echocardiographic assessment of left ventricular hypertrophy: comparison to necropsy findings. Am J Cardiol. 1986, 57: 450-458.CrossRefPubMed Devereux RB, Alonso DR, Lutas EM, Gottlieb GJ, Campo E, Sachs I, Reichek N: Echocardiographic assessment of left ventricular hypertrophy: comparison to necropsy findings. Am J Cardiol. 1986, 57: 450-458.CrossRefPubMed
18.
go back to reference Tumlin J, Stacul F, Adam A, Becker CR, Davidson C, Lameire N, McCullough PA: Pathophysiology of contrast-induced nephropathy. Am J Cardiol. 2006, 98: 14K-20K.CrossRefPubMed Tumlin J, Stacul F, Adam A, Becker CR, Davidson C, Lameire N, McCullough PA: Pathophysiology of contrast-induced nephropathy. Am J Cardiol. 2006, 98: 14K-20K.CrossRefPubMed
19.
go back to reference Dangas G, Iakovou I, Nikolsky E, Aymong ED, Mintz GS, Kipshidze NN, Lansky AJ, Moussa I, Stone GW, Moses JW, et al: Contrast-induced nephropathy after percutaneous coronary interventions in relation to chronic kidney disease and hemodynamic variables. Am J Cardiol. 2005, 95: 13-19.CrossRefPubMed Dangas G, Iakovou I, Nikolsky E, Aymong ED, Mintz GS, Kipshidze NN, Lansky AJ, Moussa I, Stone GW, Moses JW, et al: Contrast-induced nephropathy after percutaneous coronary interventions in relation to chronic kidney disease and hemodynamic variables. Am J Cardiol. 2005, 95: 13-19.CrossRefPubMed
20.
go back to reference Heyman SN, Rosenberger C, Rosen S: Regional alterations in renal haemodynamics and oxygenation: a role in contrast medium-induced nephropathy. Nephrol, Dial, Transplant. 2005, 20 (Suppl 1): i6-11.CrossRef Heyman SN, Rosenberger C, Rosen S: Regional alterations in renal haemodynamics and oxygenation: a role in contrast medium-induced nephropathy. Nephrol, Dial, Transplant. 2005, 20 (Suppl 1): i6-11.CrossRef
21.
go back to reference Gami AS, Garovic VD: Contrast nephropathy after coronary angiography. Mayo Clin Proc Mayo Clin. 2004, 79: 211-219.CrossRefPubMed Gami AS, Garovic VD: Contrast nephropathy after coronary angiography. Mayo Clin Proc Mayo Clin. 2004, 79: 211-219.CrossRefPubMed
22.
go back to reference Victor BM, Barron JT: Diastolic heart failure versus diastolic dysfunction: difference in renal function. Clin Cardiol. 2010, 33: 770-774.CrossRefPubMed Victor BM, Barron JT: Diastolic heart failure versus diastolic dysfunction: difference in renal function. Clin Cardiol. 2010, 33: 770-774.CrossRefPubMed
23.
go back to reference de Sa DD C, Hodge DO, Slusser JP, Redfield MM, Simari RD, Burnett JC, Chen HH: Progression of preclinical diastolic dysfunction to the development of symptoms. Heart. 2010, 96: 528-532.CrossRef de Sa DD C, Hodge DO, Slusser JP, Redfield MM, Simari RD, Burnett JC, Chen HH: Progression of preclinical diastolic dysfunction to the development of symptoms. Heart. 2010, 96: 528-532.CrossRef
24.
go back to reference Borlaug BA, Olson TP, Lam CS, Flood KS, Lerman A, Johnson BD, Redfield MM: Global cardiovascular reserve dysfunction in heart failure with preserved ejection fraction. J Am Coll Cardiol. 2010, 56: 845-854.CrossRefPubMedPubMedCentral Borlaug BA, Olson TP, Lam CS, Flood KS, Lerman A, Johnson BD, Redfield MM: Global cardiovascular reserve dysfunction in heart failure with preserved ejection fraction. J Am Coll Cardiol. 2010, 56: 845-854.CrossRefPubMedPubMedCentral
25.
go back to reference Borlaug BA, Paulus WJ: Heart failure with preserved ejection fraction: pathophysiology, diagnosis, and treatment. Eur Heart J. 2011, 32: 670-679.CrossRefPubMed Borlaug BA, Paulus WJ: Heart failure with preserved ejection fraction: pathophysiology, diagnosis, and treatment. Eur Heart J. 2011, 32: 670-679.CrossRefPubMed
26.
go back to reference Phan TT, Abozguia K, Nallur Shivu G, Mahadevan G, Ahmed I, Williams L, Dwivedi G, Patel K, Steendijk P, Ashrafian H, et al: Heart failure with preserved ejection fraction is characterized by dynamic impairment of active relaxation and contraction of the left ventricle on exercise and associated with myocardial energy deficiency. J Am Coll Cardiol. 2009, 54: 402-409.CrossRefPubMed Phan TT, Abozguia K, Nallur Shivu G, Mahadevan G, Ahmed I, Williams L, Dwivedi G, Patel K, Steendijk P, Ashrafian H, et al: Heart failure with preserved ejection fraction is characterized by dynamic impairment of active relaxation and contraction of the left ventricle on exercise and associated with myocardial energy deficiency. J Am Coll Cardiol. 2009, 54: 402-409.CrossRefPubMed
27.
go back to reference Afshinnia F, Spitalewitz S, Chou SY, Gunsburg DZ, Chadow HL: Left ventricular geometry and renal function in hypertensive patients with diastolic heart failure. Am J Fidney Dis. 2007, 49: 227-236.CrossRef Afshinnia F, Spitalewitz S, Chou SY, Gunsburg DZ, Chadow HL: Left ventricular geometry and renal function in hypertensive patients with diastolic heart failure. Am J Fidney Dis. 2007, 49: 227-236.CrossRef
28.
go back to reference Gajarsa JJ, Kloner RA: Left ventricular remodeling in the post-infarction heart: a review of cellular, molecular mechanisms, and therapeutic modalities. Heart Fail Rev. 2011, 16: 13-21.CrossRefPubMed Gajarsa JJ, Kloner RA: Left ventricular remodeling in the post-infarction heart: a review of cellular, molecular mechanisms, and therapeutic modalities. Heart Fail Rev. 2011, 16: 13-21.CrossRefPubMed
29.
go back to reference Melendez GC, McLarty JL, Levick SP, Du Y, Janicki JS, Brower GL: Interleukin 6 mediates myocardial fibrosis, concentric hypertrophy, and diastolic dysfunction in rats. Hypertension. 2010, 56: 225-231.CrossRefPubMedPubMedCentral Melendez GC, McLarty JL, Levick SP, Du Y, Janicki JS, Brower GL: Interleukin 6 mediates myocardial fibrosis, concentric hypertrophy, and diastolic dysfunction in rats. Hypertension. 2010, 56: 225-231.CrossRefPubMedPubMedCentral
30.
go back to reference Fang D, Hawke D, Zheng Y, Xia Y, Meisenhelder J, Nika H, Mills GB, Kobayashi R, Hunter T, Lu Z: Phosphorylation of beta-catenin by AKT promotes beta-catenin transcriptional activity. J Biol Chem. 2007, 282: 11221-11229.CrossRefPubMedPubMedCentral Fang D, Hawke D, Zheng Y, Xia Y, Meisenhelder J, Nika H, Mills GB, Kobayashi R, Hunter T, Lu Z: Phosphorylation of beta-catenin by AKT promotes beta-catenin transcriptional activity. J Biol Chem. 2007, 282: 11221-11229.CrossRefPubMedPubMedCentral
31.
go back to reference Hartog JW, Voors AA, Bakker SJ, Smit AJ, Van Veldhuisen DJ: Advanced glycation end-products (AGEs) and heart failure: pathophysiology and clinical implications. Eur J Heart Fail. 2007, 9: 1146-1155.CrossRefPubMed Hartog JW, Voors AA, Bakker SJ, Smit AJ, Van Veldhuisen DJ: Advanced glycation end-products (AGEs) and heart failure: pathophysiology and clinical implications. Eur J Heart Fail. 2007, 9: 1146-1155.CrossRefPubMed
32.
go back to reference Basta G, Schmidt AM, De Caterina R: Advanced glycation end products and vascular inflammation: implications for accelerated atherosclerosis in diabetes. Cardiovasc Res. 2004, 63: 582-592.CrossRefPubMed Basta G, Schmidt AM, De Caterina R: Advanced glycation end products and vascular inflammation: implications for accelerated atherosclerosis in diabetes. Cardiovasc Res. 2004, 63: 582-592.CrossRefPubMed
33.
go back to reference Meerwaldt R, Links T, Zeebregts C, Tio R, Hillebrands JL, Smit A: The clinical relevance of assessing advanced glycation endproducts accumulation in diabetes. Cardiovasc Diabetol. 2008, 7: 29-CrossRefPubMedPubMedCentral Meerwaldt R, Links T, Zeebregts C, Tio R, Hillebrands JL, Smit A: The clinical relevance of assessing advanced glycation endproducts accumulation in diabetes. Cardiovasc Diabetol. 2008, 7: 29-CrossRefPubMedPubMedCentral
34.
go back to reference Kamikawa A, Ishii T, Shimada K, Makondo K, Inanami O, Sakane N, Yoshida T, Saito M, Kimura K: Proinsulin C-peptide abrogates type-1 diabetes-induced increase of renal endothelial nitric oxide synthase in rats. Diabetes Metab Res Rev. 2008, 24: 331-338.CrossRefPubMed Kamikawa A, Ishii T, Shimada K, Makondo K, Inanami O, Sakane N, Yoshida T, Saito M, Kimura K: Proinsulin C-peptide abrogates type-1 diabetes-induced increase of renal endothelial nitric oxide synthase in rats. Diabetes Metab Res Rev. 2008, 24: 331-338.CrossRefPubMed
35.
go back to reference Nordquist L, Brown R, Fasching A, Persson P, Palm F: Proinsulin C-peptide reduces diabetes-induced glomerular hyperfiltration via efferent arteriole dilation and inhibition of tubular sodium reabsorption. Am J Physiol Renal Physiol. 2009, 297: F1265-1272.CrossRefPubMedPubMedCentral Nordquist L, Brown R, Fasching A, Persson P, Palm F: Proinsulin C-peptide reduces diabetes-induced glomerular hyperfiltration via efferent arteriole dilation and inhibition of tubular sodium reabsorption. Am J Physiol Renal Physiol. 2009, 297: F1265-1272.CrossRefPubMedPubMedCentral
36.
go back to reference Fiorina P, La Rocca E, Astorri E, Lucignani G, Rossetti C, Fazio F, Giudici D, Di Carlo V, Cristallo M, Pozza G, Secchi A: Reversal of left ventricular diastolic dysfunction after kidney-pancreas transplantation in type 1 diabetic uremic patients. Diabetes Care. 2000, 23: 1804-1810.CrossRefPubMed Fiorina P, La Rocca E, Astorri E, Lucignani G, Rossetti C, Fazio F, Giudici D, Di Carlo V, Cristallo M, Pozza G, Secchi A: Reversal of left ventricular diastolic dysfunction after kidney-pancreas transplantation in type 1 diabetic uremic patients. Diabetes Care. 2000, 23: 1804-1810.CrossRefPubMed
37.
go back to reference Perseghin G, Fiorina P, De Cobelli F, Scifo P, Esposito A, Canu T, Danna M, Gremizzi C, Secchi A, Luzi L, Del Maschio A: Cross-sectional assessment of the effect of kidney and kidney-pancreas transplantation on resting left ventricular energy metabolism in type 1 diabetic-uremic patients: a phosphorous-31 magnetic resonance spectroscopy study. J Am Coll Cardiol. 2005, 46: 1085-1092.CrossRefPubMed Perseghin G, Fiorina P, De Cobelli F, Scifo P, Esposito A, Canu T, Danna M, Gremizzi C, Secchi A, Luzi L, Del Maschio A: Cross-sectional assessment of the effect of kidney and kidney-pancreas transplantation on resting left ventricular energy metabolism in type 1 diabetic-uremic patients: a phosphorous-31 magnetic resonance spectroscopy study. J Am Coll Cardiol. 2005, 46: 1085-1092.CrossRefPubMed
38.
go back to reference Stewart GA, Gansevoort RT, Mark PB, Rooney E, McDonagh TA, Dargie HJ, Stuart R, Rodger C, Jardine AG: Electrocardiographic abnormalities and uremic cardiomyopathy. Kidney Int. 2005, 67: 217-226.CrossRefPubMed Stewart GA, Gansevoort RT, Mark PB, Rooney E, McDonagh TA, Dargie HJ, Stuart R, Rodger C, Jardine AG: Electrocardiographic abnormalities and uremic cardiomyopathy. Kidney Int. 2005, 67: 217-226.CrossRefPubMed
39.
go back to reference Lekawanvijit S, Adrahtas A, Kelly DJ, Kompa AR, Wang BH, Krum H: Does indoxyl sulfate, a uraemic toxin, have direct effects on cardiac fibroblasts and myocytes?. Eur Heart J. 2010, 31: 1771-1779.CrossRefPubMed Lekawanvijit S, Adrahtas A, Kelly DJ, Kompa AR, Wang BH, Krum H: Does indoxyl sulfate, a uraemic toxin, have direct effects on cardiac fibroblasts and myocytes?. Eur Heart J. 2010, 31: 1771-1779.CrossRefPubMed
40.
go back to reference Dickhout JG, Carlisle RE, Austin RC: Interrelationship between cardiac hypertrophy, heart failure, and chronic kidney disease: endoplasmic reticulum stress as a mediator of pathogenesis. Circ Res. 2011, 108: 629-642.CrossRefPubMed Dickhout JG, Carlisle RE, Austin RC: Interrelationship between cardiac hypertrophy, heart failure, and chronic kidney disease: endoplasmic reticulum stress as a mediator of pathogenesis. Circ Res. 2011, 108: 629-642.CrossRefPubMed
41.
go back to reference Zhang L, Lu Y, Wu B, Zhang S, Jiang H, Ge J, Chen H: Efficacy of statin pretreatment for the prevention of contrast-induced nephropathy: a meta-analysis of randomised controlled trials. Int J Clin Pract. 2011, 65: 624-630.CrossRefPubMed Zhang L, Lu Y, Wu B, Zhang S, Jiang H, Ge J, Chen H: Efficacy of statin pretreatment for the prevention of contrast-induced nephropathy: a meta-analysis of randomised controlled trials. Int J Clin Pract. 2011, 65: 624-630.CrossRefPubMed
42.
go back to reference Gleeson TG, Bulugahapitiya S: Contrast-induced nephropathy. AJR Am J Roentgenol. 2004, 183: 1673-1689.CrossRefPubMed Gleeson TG, Bulugahapitiya S: Contrast-induced nephropathy. AJR Am J Roentgenol. 2004, 183: 1673-1689.CrossRefPubMed
43.
go back to reference Kiski D, Stepper W, Brand E, Breithardt G, Reinecke H: Impact of renin-angiotensin-aldosterone blockade by angiotensin-converting enzyme inhibitors or AT-1 blockers on frequency of contrast medium-induced nephropathy: a post-hoc analysis from the Dialysis-versus-Diuresis (DVD) trial. Nephrol, Dial, Transplant. 2010, 25: 759-764.CrossRef Kiski D, Stepper W, Brand E, Breithardt G, Reinecke H: Impact of renin-angiotensin-aldosterone blockade by angiotensin-converting enzyme inhibitors or AT-1 blockers on frequency of contrast medium-induced nephropathy: a post-hoc analysis from the Dialysis-versus-Diuresis (DVD) trial. Nephrol, Dial, Transplant. 2010, 25: 759-764.CrossRef
Metadata
Title
Diastolic dysfunction is associated with an increased risk of contrast-induced nephropathy: a retrospective cohort study
Authors
Hyang Mo Koo
Fa Mee Doh
Kwang Il Ko
Chan Ho Kim
Mi Jung Lee
Hyung Jung Oh
Seung Hyeok Han
Beom Seok Kim
Tae-Hyun Yoo
Shin-Wook Kang
Kyu Hun Choi
Publication date
01-12-2013
Publisher
BioMed Central
Published in
BMC Nephrology / Issue 1/2013
Electronic ISSN: 1471-2369
DOI
https://doi.org/10.1186/1471-2369-14-146

Other articles of this Issue 1/2013

BMC Nephrology 1/2013 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.